Jaguar Health Reports Third Quarter 2026 Financials
Jaguar Health reported Q3 2026 total net revenue of $2.3 million, down 24% year-over-year, with prescription product revenue falling 81.9% to $0.55 million after licensing U.S. commercialization of Mytesi and Canalevia-CA1 to Future Pak. Net loss narrowed 39.6% to $5.8 million from $9.6 million a year ago, and non-GAAP recurring EBITDA loss improved to $5.0 million from $9.0 million, driven by roughly $2.0 million in operating expense reductions including dissolution of the salesforce.
Key figures
- Revenue
- 2343000
- Revenue Yoy
- -24.0%
- Product revenue net
- 551000
- Product revenue yoy
- -81.9%
- Q2 2026 product revenue
- 1200000
- License grant revenue net
- 1792000
- Prior year product revenue
- 3041000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.